We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KDP:NASDAQKeurig Dr Pepper Inc. Analysis

Data as of 2026-05-21 - not real-time

$28.48

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Keurig Dr Pepper delivered first‑quarter 2026 results that topped consensus estimates, propelling the share price up roughly 7.7% in after‑hours trading. Revenue rose 9.4% year‑over‑year to $16.94 billion, supported by a solid 53.8% gross margin and a 19.0% operating margin. Net profit margin held at 10.8% and earnings per share came in at $1.35, beating forecasts. The company also announced a quarterly dividend of $0.92, yielding about 3.2% and reinforcing its income‑oriented appeal. Analyst consensus remains a “buy” with a median price target of $33, implying roughly a 16.8% upside from the current $28.48 price. The stock now trades just above the calculated support level of $27.84, giving a modest technical cushion.
Valuation metrics show a forward P/E of 11.3 versus a trailing P/E of 21.1, suggesting the shares are undervalued relative to earnings expectations. The forward‑looking price‑to‑book of 1.53 and a dividend payout ratio of 68% are in line with peers in the consumer defensive space. Beta is exceptionally low (≈0.14), indicating limited price sensitivity to market swings, while 30‑day volatility sits near 30%, reflecting short‑term price swings. Volume trends are decreasing, which could temper liquidity, but the market cap of $38.7 billion provides a solid liquidity base. A high debt‑to‑equity ratio (≈86) and negative free cash flow raise concerns about long‑term cash generation. Overall, the blend of earnings momentum, attractive dividend yield, and a sizable upside target supports a favorable near‑term outlook, tempered by balance‑sheet pressures.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 8/10

Key Factors

  • Q1 earnings beat expectations
  • Current price above technical support with upside potential
  • Strong dividend yield

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward P/E discount to peers
  • Analyst median target price implying ~16% upside
  • Stable consumer defensive positioning

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High debt-to-equity and negative free cash flow
  • Potential dividend sustainability concerns
  • Brand portfolio resilience in a defensive sector

Key Metrics & Analysis

Financial Health

Revenue Growth9.40%
Profit Margin10.81%
P/E Ratio21.1
ROE6.31%
ROA3.61%
Debt/Equity85.98
P/B Ratio1.5
Op. Cash Flow$2.1B
Free Cash Flow$-16345499648

Technical Analysis

TrendNeutral
RSI50.9
Support$27.84
Resistance$29.68
MA 20$28.90
MA 50$27.45
MA 200$28.17
MACDBearish
VolumeDecreasing
Fear & Greed Index91.16

Valuation

Target Price$33.25
Upside/Downside16.77%
GradeUndervalued
TypeBlend
Dividend Yield3.20%

Risk Assessment

Beta0.14
Volatility29.78%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.